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Histone deacetylase (HDAC) inhibition improves function and extends survival in rodent models of a host of neurological conditions,
including stroke, and neurodegenerative diseases. Our understanding, however, of the contribution of individual HDAC isoforms to
neuronal death is limited. In this study, we used selective chemical probes to assess the individual roles of the Class I HDAC isoforms in
protectingMusmusculusprimary cortical neurons fromoxidative death.Wedemonstrated that the selectiveHDAC8 inhibitor PCI-34051
is a potent neuroprotective agent; and by taking advantage of both pharmacological and genetic tools, we established that HDAC8 is not
critically involved inPCI-34051’smechanismof action.WeusedBRD3811, an inactive ortholog of PCI-34051, and showed that, despite its
inability to inhibit HDAC8, it exhibits robust neuroprotective properties. Furthermore,molecular deletion ofHDAC8 proved insufficient
to protect neurons from oxidative death, whereas both PCI-34051 and BRD3811 were able to protect neurons derived from HDAC8
knock-outmice. Finally, we designed and synthesized two new, orthogonal negative control compounds, BRD9715 and BRD8461, which
lack the hydroxamic acidmotif and showed that they stably penetrate cellmembranes but are not neuroprotective. These results indicate
that the protective effects of these hydroxamic acid-containing small molecules are likely unrelated to direct epigenetic regulation via
HDAC inhibition, but rather due to their ability to bind metals. Our results suggest that hydroxamic acid-based HDAC inhibitors may
mediate neuroprotection via HDAC-independent mechanisms and affirm the need for careful structure–activity relationship studies
when using pharmacological approaches.
Key words: HDAC inhibitors; HDAC8; hydroxamic acids; neuroprotection; oxidative stress; PCI-34051
Introduction
Histone deacetylase inhibitors (HDACi) promote neuroprotec-
tion and improvements in function or extension of survival in
many CNS diseases (Kazantsev and Thompson, 2008; Sleiman et
al., 2009). HDACi also modulate learning and memory (Fischer
et al., 2007; Guan et al., 2009) and promote axonal regeneration
(Rivieccio et al., 2009; Gaub et al., 2010). HDACi alter gene ex-
pression profiles by facilitating chromatin remodeling through
the induction of histone acetylation (Gui et al., 2004; Sleiman et
al., 2011). HDACi also exert their effects by promoting the acet-
ylation of many nonhistone proteins (Choudhary et al., 2009),
such as transcription factors (Ryu et al., 2003; Brochier et al.,
2013) and cytoskeletal proteins (Sudo and Baas, 2010; Kim et al.,
2012).
Considering the side effects of chronic use of pan HDACi,
there has been growing interest in understanding the role of in-
dividual HDAC isoforms and developing isoform-selective
HDACi. TheHDAC superfamily includes Zn-dependentHDACs
(HDAC1–11) and NAD-dependent sirtuins. Indeed, the func-
tions of specific HDAC isoforms, including roles in memory for-
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mation and neuronal regeneration, have been studied. HDAC2
has been shown to negatively regulate memory formation by in-
hibiting the expression of synaptic plasticity genes (Guan et al.,
2009; Gra¨ff et al., 2012;Morris et al., 2013). Recently, HDAC2has
also been shown to suppress excitatory and enhance inhibitory
synapses in the hippocampus (Hanson et al., 2013). Inhibition
and deletion of HDAC6 have been shown to promote neurite
outgrowth (Rivieccio et al., 2009).
As information on the roles of HDAC isoforms accumulates,
our knowledge of the contribution of specific HDACs to neuro-
nal degeneration remains limited. There is evidence that HDAC3
is neurotoxic and that it could possibly mediate GSK3’s death-
promoting effects (Bardai andD’Mello, 2011; Bardai et al., 2012).
Moreover, recent work suggests that wild-type huntingtin pro-
tein recruits HDAC3 to prevent the latter’s toxic effect, whereas
mutant huntingtin interferes with this interaction (Bardai et al.,
2013). Although these results implicate HDAC3 in neuronal tox-
icity, a thorough analysis is still necessary to determine which
HDACs are involved in neuronal survival.
In this manuscript, we use a pharmacological toolkit of
HDACi to provide evidence that selective inhibition of individual
Class I HDAC isoforms in cortical neurons does not promote
protection against oxidative death. Furthermore, we demonstrate
that the hydroxamic acid-based HDAC8 inhibitor PCI-34051 can
mediate this neuroprotective effect via an HDAC-independent, but
hydroxamic acid-dependent, mechanism. This conclusion is sup-
ported by results showing that BRD3811, a negative control com-
pound derived from the structure of PCI-34051, protects
neurons fromoxidative stress despite lacking the ability to inhibit
HDAC8. Moreover, BRD9715 and BRD8461, two negative con-
trol compounds that lack the hydroxamic acid group of PCI-
34051, fail to protect neurons from oxidative stress. These
structure–activity relationship results suggest a model by which
these two hydroxamic acid-based compounds protect neurons
via metal chelation independent of their HDAC inhibition prop-
erties. Our results suggest that care and caution are required
when interpreting the vast literature surrounding HDACi and
suggest that combining both pharmacological and genetic studies
is necessary to understand the role of HDAC inhibition in neu-
roprotection.
Materials andMethods
Cell culture. Immature primary cortical neurons were obtained from
CD1mice (embryonic day 15 [E15]) as previously described (Ratan et al.,
1994b). The HT22 cell lines expressing either control shRNA or HDAC8
shRNA were cultured in DMEM (Invitrogen), 10% FBS (Invitrogen),
and 4 g/ml puromycin (Sigma).
Cell viability. For cytotoxicity studies, immature primary cortical neu-
rons were isolated as described above and plated at a density of 105
cells/well in 96-well plates. The next day, cells were placed in medium
containing the glutamate analog homocysteic acid (HCA 5 mM). Differ-
ent inhibitors of Class I HDACs (apicidin, PCI-34051, BRD3811) were
added at the time of HCA treatment and were present throughout the
experiment. The HDACi were prepared as 10 mM stock solutions and
serial dilutions were used to arrive to the desired concentration. The next
day, cell viability was assessed by the MTT assay (Promega) (Mosmann,
1983). The effectiveness of theMTT assays inmeasuring cell viability was
confirmed by using the LIVE/DEAD assay (Invitrogen) and fluorescence
microscopy.
Compound synthesis. PCI-34051 is commercially available. The syn-
thesis of BRD3811 is thoroughly described in (Olson et al., 2014).
Synthesis of BRD8461.Toa solutionof 1-(4-methoxybenzyl)-1H-indole-
6-carboxylic acid (50mg, 0.178mmol, 1.0 equiv), 4-dimethylaminopyridine
(4.3mg,0.036mmol,0.2equiv), and N,N-diisopropylethylamine(0.186ml,
1.07 mmol, 6 equiv) in DMF (1.8 ml) was added EDCI•HCl (68 mg, 0.355
mmol, 2 equiv). The resulting mixture was stirred for 10 min before the
addition of propylamine (0.044 ml, 0.533 mmol, 3 equiv). The reaction
was heated at 45°C overnight and then diluted in saturatedNH4Cl(aq) (50
ml). The product was extracted with EtOAc (3  50 ml). The organic
extracts were dried over MgSO4 and concentrated under reduced pres-
sure. The resulting residue was purified using preparatory HPLC to af-
ford a white solid (0.6 mg, 0.186 mol, 1%) in 95% purity (as
determined by LCMS, ESI MS: m/z: 323.6 [MH]). 1H NMR (400
MHz, CD3OD):  7.93 (s, 1H), 7.61 (d, 1H, J 8.3), 7.52 (d, 1H, J 8.5),
7.40 (d, 1H, J 3.1), 7.12 (d, 2H, J 8.5), 6.85 (d, 2H, J 8.6), 6.54 (d,
1H, J 2.8), 5.37 (s, 2H), 3.74 (s, 3H), 3.35 (t, 2H, J 7.1), 1.70–1.60 (m,
2H), 0.98 (t, 3H, J 7.4) ppm.
Synthesis of BRD9715. Lithium hydroxide (668 mg, 27.9 mmol, 20
equiv) was added to a solution of methyl 1-(4-methoxybenzyl)-1H-
indole-6-carboxylate (412 mg, 1.40 mmol, 1.0 equiv) in 27.9 ml of 2:1
THF/H2O. The resultingmixture was heated to 100°C, stirred overnight,
concentrated under reduced pressure, and diluted in saturated
NH4Cl(aq) (100 ml). The product was extracted with EtOAc (3 50ml).
The organic extracts were dried over MgSO4 and concentrated under
reduced pressure. The resulting residue was purified using flash chroma-
tography (gradient elution 100% hexanes¡ 1:1 hexanes:EtOAc) to af-
ford a white solid (154 mg, 0.547 mmol, 39%) in 95% purity (as
determined by LCMS, ESI MS: m/z: 282.8 [MH]). 1H NMR (400
MHz, CDCl3):  11.68 (br s, 1H), 8.19 (s, 1H), 7.87 (d, 1H, J 8.4), 7.68
(d, 1H, J 8.4), 7.28 (d, 1H, J 3.1), 7.10 (d, 2H, J 8.6), 6.85 (d, 2H,
J 8.6), 6.59 (d, 1H, J 3.1), 5.33 (s, 2H), 3.77 (s, 3H) ppm.
HDAC inhibition assay (microfluidic lab-on-a-chip assay). All HDACs
were purchased fromBPSBioscience.The substratesBroadSubstrateAand
Broad Substrate B were synthesized in house but can be purchased from
PerkinElmer (product #CLS960006 and #CLS960007, respectively). All
other reagents were purchased from Sigma. Caliper EZ reader II system
was used to collect all data. Compounds were tested in duplicate in a
12-point dose curvewith threefold serial dilution starting from33.33M.
Purified HDACs were incubated with 2 M carboxyfluorescein (FAM)-
labeled acetylated or trifluoroacetylated peptide substrate (Broad Sub-
strate A and B, respectively) and test compound for 60 min at room
temperature, in HDAC assay buffer that contained 50 mM HEPES, pH
7.4, 100 mM KCl, 0.01% BSA, and 0.001% Tween 20. Reactions were
terminated by the addition of the known pan HDAC inhibitor LBH-589
(panobinostat) with a final concentration of 1.5M. Substrate and prod-
uct were separated electrophoretically, and fluorescence intensity in the
substrate and product peakswas determined and analyzed by Labchip EZ
Reader. The percentage inhibition was plotted against the compound
concentration, and the IC50 values were automatically fitted byGenedata
Screener software using 4-parameter logistic dose–response model.
Glutathione measurement. Concentrations of reduced glutathione were
measured using HPLC (PerkinElmer) equipped with an 8-channel colori-
metric array detector (ESA) as previously described (Lange et al., 2008).
Briefly, cells were lysed in 5%(w/v)metaphosphoric acid and centrifuged
at 14,000 rpm for 10 min to precipitate proteins. Cell-pellet precipitates
were saved for protein determinations. Glutathione concentrations of
the supernatant fractionswere determined by injecting 5l aliquots onto
an Ultrasphere 5 u, 4.6 250mm, C18 column (Beckman Coulter), and
eluting with amobile phase of 50mMNaH2PO4, 0.05mM octane sulfonic
acid, 1.5% acetonitrile, pH 2.62, at a flow rate of 1 ml/min. Peak areas
were analyzed using software from ESA.
Immunoblot analysis. To determine acetyl tubulin protein levels, total
cell proteins were prepared by lysing cells in 1% Triton buffer (25 mM
Tris pH 7.4, 100 mM NaCl, 1 mM EGTA, 1% Triton X-100, protease
inhibitors, 2.5 mM sodium orthovanadate). To determine acetyl histone
H4 protein levels, total cell proteins were prepared by lysing the cells in
RIPA-B (1% Triton X-100, 1% SDS, 50 mM Tris-Cl, pH 7.4, 500 mM
NaCl, and 1mM EDTA) followed by benzonase nuclease digestion for 15
min. To determine HDAC8 protein levels, nuclear and cytoplasmic pro-
teins were obtained using NE-PER Nuclear and Cytoplasmic Extraction
Reagents (Pierce Biotechnology) in the presence of protease inhibitors,
the proteasome inhibitorMG-132, andphosphatase inhibitors according
to the manufacturer’s protocol. To determine acetylated smc-3 protein
levels, total cell proteins were prepared by lysing cells first in buffer A (10
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mM HEPES, pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10%
glycerol, 0.1% Triton X-100, 1 mM DTT, protease inhibitors, PMSF,
MG132, sodium orthovanadate). Next, nuclear proteins were extracted
in buffer B (3mMEDTA, 0.2mM EGTA, 0.3 MNaCl, 1mMDTT, protease
inhibitors, PMSF,MG132, sodium orthovanadate). Samples were boiled
in Laemmli buffer and electrophoresed under reducing conditions on
NuPAGENovex 4%–12%Bis-Tris Gel polyacrylamide gels (Invitrogen).
Proteins were transferred to a nitrocellulose membrane (Bio-Rad) by
electroblotting. Nonspecific binding was inhibited by incubation in
Odyssey blocking buffer (LI-COR Biosciences). Antibodies against
acetylated tubulin (clone 6-11B-1; Sigma), tubulin (Sigma), histone H4
(05-858R, Millipore), acetyl histone H4 (06-866, Millipore), SMC-3
(A300-060A, Bethyl Laboratories), acetyl SMC-3 (PD040, MBL), and
-actin (AC-74; Sigma-Aldrich) were diluted 1:1000, 1:1000; 1:1000,
1:2000, 1:2000, 1:1000, and 1:10,000, respectively, in odyssey blocking
buffer, and the membranes were incubated overnight at 4°C.
Fluorophore-conjugated Odyssey IRDye-680 or IRDye-800 secondary
antibody (LI-CORBiosciences)was used at 1:10,000 dilution followed by
incubation for 1 h at room temperature. Finally, proteins were detected
using an Odyssey infrared imaging system (LI-COR Biosciences).
Immunoprecipitation.The 200g of nuclear proteins was diluted in 50
mM Tris-HCl, pH 7.4, in the presence of protease inhibitors (Sigma),
PMSF, MG132, and sodium orthovanadate and precleared with beads
(Santa Cruz Biotechnology) for 30 min and immunoprecipitated with 1
g of SMC-3 antibody overnight.
HDAC8 shRNA knockdown. HT22 hippocampal neuron cells were
transfected with MISSION HDAC8 (NM_027382.3) validated shRNA
plasmidDNA (Sigma-Aldrich) using Lipofectamine 2000 (Invitrogen) in
accordance with the manufacturer’s protocol. Stably transfected HT22
neuronswere selected over several weeks by the addition of puromycin (4
g/ml) to the culture medium. Puromycin-resistant clones were pooled
to avoid confounds introduced by clonal selection, and HDAC8 knock-
down was verified by Western blotting. Three sequences were respec-
tively used and analyzed. In addition, MISSION Non-Target shRNA
Control Vector (SHC002) (Sigma-Aldrich) was used as a negative con-
trol. This vector contains an shRNA insert that does not target human
and mouse genes. In addition, cells were treated with 5 mM HCA over-
night in the presence of the HDAC8 inhibitor PCI-34051 and viability
was assessed using the MTT assay.
HDAC8 conditional knock-out. HDAC8-floxed mice were a kind gift
fromDr. Eric Olson (Haberland et al., 2009). Heterozygous females were
mated with males carrying tamoxifen-inducible Cre-mediated recombi-
nation system driven by the chicken  actin promoter/enhancer coupled
with the cytomegalovirus immediate-early enhancer. Tamoxifen (3
mg/40 g weight) was administered to the pregnant mouse when the
embryos were at E13. Tamoxifen will induce Cre recombination in de-
veloping embryos of treated mothers (Hayashi and McMahon, 2002).
Two days later, the pregnant mother was killed and each individual E15
embryo cortex was used to make primary cortical neurons as described
above. Considering that the HDAC8 gene is located on the X chromo-
somes of mice, we expect that half of the male embryos to be wild-type
and the other half to be HDAC8-floxed males. We genotyped each
embryo for the presence of the HDAC8-floxed gene and the tamoxifen-
inducible Cre recombinase gene (primers: 5-TCAGCCTTGGATATG
CTAGCC-3;5-TTGCCAGAGTAGACCTAAGTGCT-3;5-TCCTGTT
TCTAGAGCCACATCC-3). Cultures derived from embryos having the
HDAC8-floxed gene and lacking the Cre recombinase gene served as
controls, and cultures derived from embryos carrying both the HDAC8-
floxed gene and the Cre recombinase gene served as the experimental
group. HDAC8 knockdown was assessed by both real time RT-PCR
(primers: 5-GAATATGGACTAGGTTATGACTGCCCAG-3 and 5-
GCTACTTTACACTTCCCGTCAATCAG-3) and Western blots.
Statistical analysis. One-way or two-way ANOVA followed by the
Dunnett or Bonferroni post tests, respectively, were used to measure
statistical significance. p  0.05 was considered to be statistically
significant.
Results
The Class I HDAC inhibitor apicidin protects against
oxidative death in cortical neurons
Previously, we as well as others have shown that broad-spectrum
HDACi are neuroprotective in mouse models of neurodegenera-
tive diseases, such asHuntington’s disease and in stroke (Ferrante
Figure 1. The Class I HDAC inhibitor apicidin potently protects primary immature cortical
neurons fromglutathionedepletion-induceddeath.A, Chemical phylogeny treewith respective
Kis. Larger red circles represent lower Kis. B, Apicidin protects primary cortical neurons from
glutathione depletion-induced death in a concentration-dependent manner. Cell death was
measured 24 h after treatmentwith the glutamate analogHCAwith orwithout the Class I HDAC
inhibitor apicidin by monitoring MTT reduction. Significant protection compared with HCA-
treated cells: **p 0.01; ****p 0.0001. C, Apicidin protects primary cortical neurons from
glutathionedepletion-induceddeath asmonitoredby calcein fluorescence (green fluorescence,
to detect live cells) andethidiumhomodimer staining (red fluorescence, to detect dead cells).D,
Apicidin protects primary cortical neurons from oxidative deathwithout increasing glutathione
levels. Total reduced glutathionewasmeasured byHPLC. Apicidin reduced glutathione levels in
vehicle-treated cortical neurons but does not affect the ability of HCA to deplete reduced glu-
tathione. Significant glutathione levels compared with HCA-treated cells: ****p 0.0001.
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et al., 2003; Ryu et al., 2003; Kazantsev and Thompson, 2008;
Sleiman et al., 2011). Although their neurotherapeutic potential
is promising, these compounds inhibit multiple HDAC isoforms
and disrupt cellular processes that depend on protein acetylation,
many of whichmay not be involved in neuronal toxicity or death.
Indeed, over the past few years, evidence has accumulated sug-
gesting that acetylation is a modification that rivals phosphory-
lation in terms of scope and importance (Kouzarides, 2000;
Choudhary et al., 2009). This has emphasized the urgent need for
isoform-selectiveHDACi. Isoform-selective
HDACimay alter pathways specifically in-
volved in neuronal death, and therefore,
could provide a wider therapeutic value
compared with the compounds currently
available.
The need for such inhibitors has
heightened interest in understanding the
functions of the different HDAC iso-
forms, in part, by synthesizing isoform-
selective HDACi. Considering the central
role that oxidative stress plays in neuronal
death due to both chronic and acute in-
sults to the brain, we have been interested
in studying the mechanisms underlying
HDAC inhibitor-mediated neuroprotec-
tion from oxidative death. Our goals in
this study were as follows: (1) to use a sys-
tematic approach using isoform-selective
HDACi to identify the HDAC isoform(s)
involved in oxidative death in cortical
neurons; (2) to identify the pathways af-
fected by the culprit HDAC(s) underlying
the neuroprotection; and (3) to assess the
potential of targeting specific HDACs for
neuroprotection. Some evidence impli-
cating particular HDAC isoforms, such as
HDAC1 (Bardai et al., 2012), HDAC3
(Bardai et al., 2013), and HDAC6 (Riviec-
cio et al., 2009), has been reported.
To refine our understanding of which
HDACs are relevant in oxidative stress-
induced neurodegeneration, we used an
established in vitromodel of neuronal ox-
idative death. Early in their development
in culture, cortical neurons exposed con-
tinuously to glutamate (or the glutamate
analog homocysteic acid [HCA]) suc-
cumb through a mechanism dependent
on competitive inhibition of cystine
transport (Ratan et al., 1994b). Reduced
intracellular cyst(e)ine leads to depletion
of the antioxidant glutathione. Cell death
attributable to glutathione depletion has
features of apoptosis and can be com-
pletely prevented by classical antioxidants
(Ratan et al., 1994a). We have previously
shown that nonselective HDACi, such as
trichostatin A (TSA), suberoylanilide hy-
droxamic acid, or Scriptaid protect
neurons against glutathione depletion-
induced neuronal death (Ryu et al., 2003;
Langley et al., 2008; Sleiman et al., 2011).
Considering that HDAC6, a Class IIb
HDAC, has been shown to play a role in neuroprotection (Riviec-
cio et al., 2009), we focused on Class I HDACs. To determine
whether the Class I HDACs are involved in this neuroprotection,
we treated primary cortical neurons with HCA (a glutamate an-
alog, 5 mM) alone or with varying concentrations of apicidin, an
HDAC inhibitor specific for the Class I isoforms (Bradner et al.,
2010) (Fig. 1A), and then assessed cell death quantitatively and
qualitatively usingMTT reduction and LIVE/DEAD staining, re-
spectively. We observed that apicidin potently protects neurons
Figure 2. The HDAC8 inhibitor PCI-34051 protects primary immature neurons from glutathione depletion-induced death
without restoring glutathione levels. A, Structure of PCI-34051. B, Chemical phylogeny tree with respective Kis. Larger red circles
represent lower Kis. C, PCI-34051 protects primary cortical neurons from glutathione depletion-induced death in a concentration-
dependentmanner. Cell deathwasmeasured24hafter treatmentwith theglutamate analogHCAwithorwithoutHDAC8 inhibitor
PCI-34051 bymonitoringMTT reduction. Significant protection comparedwith HCA-treated cells: **p 0.01; ***p 0.0001.D,
PCI-34051 protects primary cortical neurons from glutathione depletion-induced death as monitored by calcein fluorescence
(green fluorescence, to detect live cells) and ethidium homodimer staining (red fluorescence, to detect dead cells). E, PCI-34051
protects primary cortical neurons from oxidative death without increasing glutathione levels. Total reduced glutathione was
measured by HPLC. PCI-34051 reduced glutathione levels in vehicle-treated cortical neurons but does not affect the ability of HCA
to deplete reduced glutathione. Significant glutathione levels compared with HCA-treated cells: ****p 0.0001. F, PCI-34051
protects primary cortical neurons from glutathione depletion-induced death independent of glutathione synthesis. Buthionine
sulfoximine (BSO), an inhibitor of glutathione synthesis, did not affect PCI-34051’s ability to protect neurons fromoxidative death.
Cell death was measured 24 h after treatment with the glutamate analog HCA with or without HDAC8 inhibitor PCI-34051 by
monitoring MTT reduction. Significant protection compared with HCA-treated cells: ****p 0.0001.
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from oxidative stress-induced neuronal death (Fig. 1B,C). The
protective effect of Apicidin occurred without restoration of glu-
tathione levels in the neurons, suggesting that apicidin protects
neurons downstream of glutathione depletion, and not by pre-
venting the ability of glutamate or its analogs (HCA) to inhibit
cystine uptake (Fig. 1D).
The HDAC8 selective inhibitor PCI-34051 protects against
oxidative death in cortical neurons
To further characterize the specificHDAC isoform(s) involved in
mediating oxidative death in cortical neurons, we used a phar-
macological approach. Using available ortho-aminoanilide in-
hibitors targeting HDAC1, HDAC1HDAC2, and HDAC3, we
did not observe any protection against
glutathione depletion-induced neuronal
death (data not shown).We next tested an
established and highly selective HDAC8
inhibitor, PCI-34051, a hydroxamic acid-
based HDAC inhibitor (Fig. 2A). PCI-
34051 was first identified as a HDAC8
selective inhibitor with a specificity of
200-fold over otherHDAC inhibitors in
in vitro assays. It was also established that
the use of PCI-34051 phenocopied the ef-
fects obtained with HDAC8 knockdown
in HeLa cells, such as lack of histone acet-
ylation, lack of tubulin acetylation, and
induction of apoptosis in T-cell lym-
phomas (Balasubramanian et al., 2008).
Moreover, like HDAC8 knockdown, PCI-
34051 induced smc-3 acetylation in mul-
tiple cell types (Deardorff et al., 2012;
Olson et al., 2014). Biochemical assays re-
vealed that PCI-34051 was very potent
and inhibited HDAC8 with a Ki in the
nanomolar range (Table 1; Fig. 2B). We
treated primary cortical neurons with
HCA (5 mM) alone or with varying con-
centrations of PCI-34051 and then as-
sayed cell death usingMTT reduction and
LIVE/DEAD staining (Fig. 2C,D). We ob-
served that treatment with PCI-34051
protects against oxidative death in cortical
neurons (Fig. 2C,D), and like apicidin,
does not prevent the decrease in glutathi-
one levels resulting from HCA treatment
(Fig. 2E), suggesting that PCI-34051-
mediated neuroprotection occurs down-
stream of depletion of glutathione levels.
Indeed, PCI-34051 protected neurons
from oxidative death even in the presence
of buthionine sulfoximine, an inhibitor
of gamma-glutamylcysteine synthetase
(gamma-GCS), the rate-limiting step in
glutathione synthesis (Fig. 2F). These
findings confirm that PCI-34051 protects
independently of increasing glutathione
levels. Interestingly, however, considering
that the apicidin concentrations required
for neuroprotection were consistent with
its ability to inhibit HDACs, the relatively
high concentrations of PCI-34051 (M)
required for the same effect were suspi-
Figure 3. Validation of the PCI-34051 and BRD3811 behavior in neurons. A, Structure of BRD3811. B, Chemical phylog-
eny tree with respective Kis. Larger red circles represent lower Kis. C, PCI-34051 and BRD3811 do not increase total histone
H4 acetylation, whereas the broad-spectrum HDAC inhibitor TSA significantly increased total histone H4 acetylation. Bar
graphs represent the quantification results of three independent Western blots. Significant increases in histone H4 acet-
ylation compared with control: *p  0.05. D, PCI-34051 and BRD3811 do not affect tubulin acetylation, whereas TSA,
known to robustly inhibit HDAC6, significantly increased tubulin acetylation. Bar graphs represent the quantification
results of three independent Western blots. Significant increases in histone H4 acetylation compared with control: *p
0.05. E, PCI-34051 induces the acetylation of SMC-3, an HDAC8 target, whereas BRD3811 does not. This suggests that
PCI-34051 inhibits HDAC8, whereas BRD3811 does not. Bar graphs represent the quantification results of three indepen-
dent Western blots.
Table 1. Comparison of HDAC inhibition constant for compounds used in this study
HDAC Apicidin PCI-34051 BRD3811 BRD9715 BRD8461
1 0.0003 0.0002 24.4 12.8 25 25 25
2 0.0009 0.0006 17.8 15.4 25 25 25
3 0.0007 0.0006 25 25 25 25
4 25 25 25 25 25
5 24.5 1.82 25 25 25 25
6 1.74 0.763 7.92 5.13 25 25 25
7 25 25 25 25 25
8 0.283 0.076 0.011 0.006 25 25 25
9 25 25 25 25 25
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cious. For this reason, we further investigated the mechanism of
action of PCI-34051.
BRD3811, a structural analog of PCI-34051, that does not
inhibit HDAC8, protects against oxidative death in cortical
neurons
To better understand the mechanism of action of PCI-34051, we
reasoned that the use of an inactive ortholog of PCI-34051 that
retained the zinc chelating hydroxamic acidmotif would allow us
to assess the specific role of HDAC8 inhibition in neuroprotec-
tion from oxidative death. We used an analog, BRD3811 (Olson
et al., 2014). This compound has the same structure as PCI-34051
with the exception of an additional methyl group ortho to the
hydroxamic acid (Fig. 3A). The presence of this methyl group
prevents BRD3811 from accessing the tu-
bular pocket of HDAC8 to coordinate
zinc in the active site (Olson et al., 2014).
Indeed, biochemical assays demonstrate
that BRD3811 does not inhibit anyHDAC
(Table 1; Fig. 3B) (Olson et al., 2014), a
result that is in stark contrast to PCI-
34051, which inhibits HDAC8 in the
nanomolar range.
To verify in cortical neurons that PCI-
34051 selectively inhibits HDAC8 and
BRD3811 does not, we examined the acet-
ylation status of a number of proteins. It
is well established that broad-spectrum
HDACi induce acetylation of histone H4.
Knockdown of HDAC8, on the other
hand, does not induce any histone H4
acetylation (Oehme et al., 2009). As pre-
dicted, TSA significantly induced histone
H4 acetylation, whereas both PCI-34051
and BRD3811 did not (Fig. 3C). More-
over, considering that many of the known
HDAC6 inhibitors are hydroxamic acids
and that both PCI-34051 and BRD3811
are hydroxamic acids, we next evaluated
the possibility that our inhibitors affect
HDAC6 to mediate neuroprotection. Tu-
bulin is an established HDAC6 target. In-
hibition of HDAC6 by selective inhibitors
or by broad-spectrum inhibitors, such as
TSA, enhances tubulin acetylation (Fig.
3D). As expected, both PCI-34051 and
BRD3811 did not induce tubulin acetyla-
tion. Finally, to validate that PCI-34051 is
a specific HDAC8 inhibitor, whereas
BRD3811 does not inhibit HDAC8, we
tested whether these compounds can in-
duce the acetylation of a defined HDAC8
target, SMC-3. SMC-3, a member of the
cohesin complex, is among the few in vivo
validated HDAC8 target proteins (Dear-
dorff et al., 2012). We immunoprecipi-
tated SMC-3 from cortical neurons
treated with PCI-34051 or BRD3811 and
then assessed SMC-3 acetylation using an
acetyl SMC-3 antibody. Only PCI-34051
induced SMC-3 acetylation, whereas
BRD3811 did not (Fig. 3E). This result
was also confirmed using mass spectrom-
etry analysis of proteins acetylated by PCI-34051 treatment and
not by BRD3811 (Olson et al., 2014). These results, along with
microarray data (S.F.S. and R.R.R., unpublished data) demon-
strating that the transcriptional responses induced by PCI-34051
and BRD3811 in neurons are highly distinct, clearly demonstrate
that, even though PCI-34051 and BRD3811 have similar struc-
tures, the first is a specificHDAC8 inhibitorwhereas the second is
not.
To determine whether the protection from oxidative stress-
induced neuronal death observed with PCI-34051 is specifically
due to its ability to inhibit HDAC8, we tested whether BRD3811,
the inactive ortholog of PCI-34051, could protect primary corti-
cal neurons against oxidative death. Surprisingly, BRD3811 pro-
tected cortical neurons from glutathione depletion-induced
Figure 4. The newly synthesized PCI-34051 structural analog BRD3811 protects primary immature neurons from glutathione
depletion-induced death without restoring glutathione levels. A, BRD3811 protects primary cortical neurons from glutathione
depletion-induceddeath in a concentration-dependentmanner. Cell deathwasmeasured24hafter treatmentwith theglutamate
analog HCA with or without BRD3811 by monitoring MTT reduction. Significant protection compared with HCA-treated cells:
**p 0.01; ***p 0.0001; ****. B, BRD3811 protects primary cortical neurons from glutathione depletion-induced death as
monitored by calcein fluorescence (green fluorescence, to detect live cells) and ethidiumhomodimer staining (red fluorescence, to
detect dead cells). C, BRD3811 protects primary cortical neurons from oxidative deathwithout increasing glutathione levels. Total
reducedglutathionewasmeasuredbyHPLC. BRD3811doesnot affect the ability ofHCA todeplete reducedglutathione. Significant
glutathione levels compared HCA-treated cells: *p 0.05; ****p 0.0001. D, BRD3811 protects primary cortical neurons from
glutathione depletion-induced death independent of glutathione synthesis. Buthionine sulfoximine (BSO), an inhibitor of gluta-
thione synthesis, did not affect PCI-34051’s ability to protect neurons from oxidative death. Cell death was measured 24 h after
treatment with the glutamate analog HCA with or without BRD3811 by monitoring MTT reduction. Significant protection com-
pared with HCA-treated cells: ****p 0.0001.
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neuronal death (Fig. 4A,B). Like PCI-
34051, BRD3811’s neuroprotective effect
was independent of glutathione (Fig.
4C,D). Considering that the concentra-
tions of PCI-34051 and BRD3811 re-
quired for neuroprotection were identical
(5–10 M), our results suggest that a
mechanism independent from HDAC8
inhibition accounts for both PCI-34051
and BRD3811’s neuroprotective effects.
HDAC8 knockdown does not protect
cortical neurons against glutathione
depletion-induced death
To investigate the role of HDAC8 in oxi-
dative stress-induced neuronal death di-
rectly, we reduced HDAC8 gene
expression using RNA interference. We
first knocked down HDAC8 in HT22
cells, an immortalized hippocampal neu-
ronal cell line. We chose to perform the
experiments in this cell line because it is
well documented that glutathione deple-
tionmediates cellular death in this cell line
by affecting the same molecular pathways
it does in neurons and because of the ease
of transfection methods in cell lines com-
pared with primary neurons. We con-
firmed HDAC8 protein knockdown (Fig.
5A) and tested whether HDAC8 knock-
down protected against oxidative death.
HDAC8 knockdown did not protect
HT22 cells from oxidative stress-induced
death (Fig. 5B).Moreover, PCI-34051was
able to significantly protect the cells even
when HDAC8 levels were reduced, sug-
gesting that PCI-34051’s neuroprotective
effect is independent from HDAC8 inhi-
bition. To rule out that the neuroprotec-
tive effect of PCI-34051 is dependent on
its ability to inhibit residual HDAC8 ac-
tivity in the knockdown cells, we reasoned
that, if PCI-34051 mediates neuroprotec-
tion by inhibiting residual HDAC8 activ-
ity in the HDAC8 knockdown cells, then
we would expect to observe that lower
doses of PCI-34051 significantly mediate
neuroprotection in HDAC8 knockdown
cells compared with wild-type cells. In-
deed, we did not observe any changes in
the PCI-34051 neuroprotective dose–re-
sponse, suggesting that the compound’s
neuroprotective effect is independent
from inhibition of residual HDAC8 activity (Fig. 5C). To further
exclude a role for HDAC8 in oxidative death, we confirmed these
results in cortical neurons derived from conditional HDAC8
knock-out mice. We confirmed knockdown in these neurons by
real-time RT-PCR (Fig. 5D). Similar to the results obtained in
HT22 cells, HDAC8 knockdown in cortical neurons, did not pro-
tect against oxidative stress-induced death (Fig. 5E). In addition,
both PCI-34051 and BRD3811 continued to protect neurons
from oxidative death independent of HDAC8 levels. These re-
sults support the conclusion that HDAC8 is not amajor player in
oxidative stress-induced neuronal death. However, the precise
mechanism for protection by PCI-34051 andBRD3811 remained
unclear.
PCI-34051 and BRD3811mediate neuroprotection via their
hydroxamic acid group
When choosing to use BRD3811, we made a conscious decision
to preserve the hydroxamic acid moiety of PCI-34051, as we felt
that this functional groupwould be themost likely contributor to
any off-target effects (Olson et al., 2014). However, when our
Figure 5. HDAC8 knockdown does not protect cells from glutathione depletion-induced death. A, HT22 cells were stably
transfected with shRNA against HDAC8, and knockdown was assessed in both the cytosolic and nuclear fractions using Western
blots. Indeed, HDAC8 levelswere significantly reduced in both cell fractions.B, Knockdown of HDAC8 in HT22 cells does not protect
against glutathione depletion-induced death. Moreover, PCI-34051 can still significantly protect cells against glutathione
depletion-induced neuronal death even when HDAC8 levels were reduced, suggesting that the neuroprotective functions of
PCI-34051are independent of its ability to inhibit HDAC8. Cell deathwasmeasured24hafter treatmentwith theglutamate analog
HCAwithorwithoutPCI-34051bymonitoringMTT reduction. Significant protection comparedwithHCA-treated cells: **p0.01;
***p 0.0001. C, The same concentrations of PCI-34051were required tomediate protection against oxidative death both in Ctrl
shRNA and HDAC8 shRNA cells, suggesting that PCI-34051 mediates neuroprotection independent of any inhibition of residual
HDAC8 activity. D, Knock-out of HDAC8 in primary cortical neurons was established by real-time RT-PCR. Significant knockdown
comparedwithCre-/Cre-;HDAC8LoxP/Y cells: **p0.01.E, Knock-outofHDAC8 inprimary cortical neuronsdoesnotprotect from
glutathione-induced death. Moreover, both PCI-34051 and BRD3811 can still significantly protect cells against glutathione
depletion-inducedneuronal death, suggesting that theneuroprotective functions of bothPCI-34051 andBRD3811are independent from
their ability to inhibit HDAC8. Cell deathwasmeasured24hafter treatmentwith theglutamate analogHCAwithorwithout PCI-34051or
BRD3811bymonitoringMTT reduction. Significant protection comparedwithHCA-treated cells: *p 0.05; **p 0.01.
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studies revealed that neuroprotection mediated by PCI-34051
and BRD3811 was not the result of HDAC8 inhibition, we de-
cided to more thoroughly investigate the role of the hydroxamic
acid group. Therefore, we designed and synthesized BRD9715
and BRD8461, two additional orthologs of PCI-34051 in which
we replaced the hydroxamic acidmoiety with a nonchelating acid
(Fig. 6A) or propylamide group (Fig. 6C). We ensured that these
two compounds were permeable and stable (data not shown).
Not surprisingly, replacement of the hydroxamic chelating moi-
ety with the acid or propylamide groups ablated all HDAC bind-
ing activity (Table 1). As anticipated, BRD9715 and BRD8461
failed to protect primary cortical neurons from oxidative death,
suggesting that the hydroxamic acid group in PCI-34051 and
BRD3811 is indeed critical for neuroprotection (Fig. 6B,D).
Discussion
Evidence suggests that environmental factors may contribute to
neurodegeneration through changes in epigenetic modifications,
such as DNA methylation, and histone acetylation. The induc-
tion of epigenetic changes is thought to induce alterations in gene
expression programs. Epigenetic regulation has garnered signifi-
cant attention because molecules that regulate epigenetic path-
ways, such as HDACs, appear to play important roles in disease
progression both in in vitro and in vivo models of CNS diseases.
Using various methods, several groups have demonstrated that
HDACi ameliorate the symptoms of many chronic and acute
CNS diseases, including Alzheimer’s disease and Huntington’s
disease and have implicated specific HDAC isoforms in these
pathological processes. Indeed, there has been an urgent call to
develop isoform-selective HDACi to study the role of individual
HDACs and to potentially assess the therapeutic potential of such
compounds. Here, we used a selective HDAC8 inhibitor and
three distinct inactive structural orthologs to illustrate that a de-
gree of caution is required when interpreting the effects of phar-
macological modulators and the roles of their primary biological
targets, in this case specific HDAC isoforms. Our results empha-
size the importance of careful validation of structure–activity re-
lationship studies when using pharmacological approaches to
answer a biological question. We used several isoform-selective
HDACi in an attempt to identify the Class I HDAC(s) involved in
glutathione depletion-induced neuronal death (Fig. 1; and data
not shown). We showed that PCI-34051, a compound that has
been widely used as a potent and highly selective HDAC8 inhib-
itor (Fig. 2), protects murine cortical neurons from oxidative
stress. It was only when we used BRD3811 (Fig. 3), a compound
derived from PCI-34051, but lacking the latter’s ability to inhibit
HDAC8, that we discovered that HDAC8 inhibition is not the
“on-target” neuroprotective effect of this compound (Fig. 4).We
confirmed this finding by showing that HDAC8 knockdown in
neurons does not protect against oxidative death (Fig. 5). Finally,
we designed and synthesized BRD9715 and BRD8461, two addi-
tional structural analogs of PCI-34051 lacking the hydroxamic
acid chelating motif and devoid of any HDAC inhibitory activity
to show that the mechanism of neuroprotection from oxidative
death is dependent on the hydroxamic acid groups of PCI-34051
and BRD3811 (Fig. 6). Our results led us to reassess the data pub-
lished, especially with respect to hydroxamic acid-containing
HDACi.
Even though the role of someHDAC isoforms inCNSdiseases
has been established through genetic knock-out or knockdown
studies, the vast majority of studies have used HDACi to show
protective effects in CNS diseases and cancer. Of these studies, a
limited number have actually shown that these compounds pro-
tect neurons by inhibiting a HDAC or a subset of HDACs and
have tested the compounds in genetic knock-outs of specific
HDACs. Such studies, though, are complicated, especially when
more than oneHDACcontributes to the disease or the inhibitor’s
protective effect. The design of structurally similar, yet pharma-
cologically inert, compounds could indeed alleviate some of the
difficulties of such experiments. Indeed, nullscript, a hydroxamic
acid that shares a similar structure to the HDAC inhibitor
Scriptaid and that is however unable to inhibit HDACs in the
same concentration range as Scriptaid, serves as an ideal negative
control to identify the HDAC inhibition “on-target” effects of
Scriptaid. By using BRD3811 as a negative control for PCI-34051,
we are now poised to identify HDAC8 target genes in neurons, a
finding that has been elusive so far in neurons. Mutations affecting
the histone deacetylase domain of HDAC8 have been reported to
cause Cornelia de Lange syndrome, a disease characterized by
craniofacial abnormalities andmental retardation inchildren(Dear-
dorff et al., 2012). Identification of HDAC8 target genes in neurons
will shed light on themolecularmechanismsunderlying this disease.
In addition to identifying HDAC target genes, the develop-
ment of carefully designed negative control compounds will help
identify key functional motifs necessary for neuroprotection. In-
deed, by designing compounds in which the hydroxamic acid
moiety of PCI-34051 and BRD3811 was converted to an acid or a
propylamide group (Fig. 6), wewere able to provide evidence that
the hydroxamic acid moiety of these compounds is necessary for
their neuroprotective effect. The hydroxamic acid moiety can be
a promiscuous chemical motif that has been shown to have a
strong ability to chelate metals, including iron or zinc outside the
context of the HDAC enzyme family. Because the glutathione
depletion-induced neuronal death is known to be iron-dependent
(Dixon et al., 2012) and because the concentrations at which the
HDACi are neuroprotective (M) are more consistent with the cel-
Figure6. The hydroxamic acid group of PCI-34051 andBRD3811 is necessary for their ability
to protect against glutathionedepletion-inducedneuronal death.A, Structure of BRD9715. This
compound only differs from PCI-34051 by the conversion of the hydroxamic acid group to an
acid group. B, BRD9715 does not protect primary cortical neurons from glutathione depletion-
induced neuronal death. C, Structure of BRD8461. This compound only differs from PCI-34051
by the conversion of the hydroxamic acid group to a propylamide group. D, BRD8461 does not
protect primary cortical neurons from glutathione depletion-induced neuronal death. Cell
death was measured 24 h after treatment with the glutamate analog HCA with or without
BRD9715or BRD8461bymonitoringMTT reduction. Significant protection comparedwithHCA-
treated cells: ****p 0.0001.
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lular concentration of chelatable iron than their HDAC potencies
(nM), we speculate that an alternative mechanism involving iron
might be responsible for the neuroprotective properties of these
compounds (D.E.O. et al., manuscript in preparation).
In the CNS, iron is important for many cellular processes,
including gene expression, DNA synthesis, mitochondrial elec-
tron transport, and other metabolic processes. Iron accumula-
tion and deposition play important roles in the progression of
neurodegeneration (Weinreb et al., 2010). High concentrations
of iron react with hydrogen peroxide in the Haber-Weiss/Fenton
reaction to produce hydroxyl radicals and in turn lead to oxida-
tive stress and cellular death (Smith et al., 1997). As such, a wealth
of data indicates that molecules capable of chelating iron can
mediate neuroprotection (Weinreb et al., 2010). In addition to
the induction of oxidative stress, iron plays important roles as a
substrate to enzymes, such as the iron-dependent dioxygenases,
such as hypoxia inducible factor (HIF)-prolyl-4-hydroxylases
(HIF-PHDs) and the Tet proteins. HIF-PHD inhibition by iron
chelators, such as deferoxamine, has been shown to be protective
against oxidative death (Aminova et al., 2008; Siddiq et al., 2009).
Considering that modeling analysis suggested that PCI-34051
and BRD3811 may inhibit HIF-PHDs, we have tested whether
these compounds can stabilize HIF1 and whether they can pro-
tect neurons derived fromHIF-PHD triple knock-out mice. Our
results suggest that the mechanism of protection is independent
fromHIF-PHD inhibition (S.F.S. and R.R.R., unpublished data).
However, it remains a strong possibility that metal chelation ei-
ther to reduce ROS or to interfere with enzymatic reactions in the
ERK/MAPK pathway could be a way by which the hydroxamic
acids PCI-34051 and BRD3811 are neuroprotective. One possi-
bility by which these compounds can interfere with ERK phos-
phorylation is through inhibition of 12-lipoxygenase. Indeed, 12/
15-lipoxygenases have been implicated in diabetes-induced ERK
phosphorylation in the peripheral nerve and dorsal root ganglion
neurons (Stavniichuk et al., 2012), and hydroxamic acids through
their iron-chelating abilities can act as lipoxygenase inhibitors (Dai-
ley and Imming, 1999). Interestingly, 12-lipoxygenase is a well-
established mediator of glutathione depletion-induced neuronal
death and 12-lipoxygenase inhibitors are neuroprotective (Li et al.,
1997). In separate studies, we did not find that PCI-34051 and
BRD3811 inhibit recombinant 12-lipoxygenase activity (Sleiman,
Holman, and Ratan, unpublished observations).
Together, our findings suggest that hydroxamic acids may
mediate neuroprotection at least in part through HDAC-
independent mechanisms. We speculate that these mechanisms
may involve the ability of these molecules to sequester iron
(D.E.O. et al., manuscript submitted). Even though our data sug-
gest that some hydroxamic acid HDAC inhibitors protect via a
mechanism independent of HDAC inhibition, our prior pub-
lished data established the importance of inhibiting HDACs for
neuroprotection from oxidative stress. Indeed, Scriptaid is a hy-
droxamic acid HDAC inhibitor that protects against neuronal
oxidative death, whereas Nullscript, its negative control ortholog
that still retains the hydroxamic acid side chain of Scriptaid but
lacks the ability to inhibit HDACs at comparable doses does not
protect neurons against oxidative death. This, along with our
observation that nonhydroxamic acid HDAC inhibitors, such as
Apicidin (Fig. 1) or sodium butyrate (Ryu et al., 2003), protects
against neuronal oxidative death suggests that HDACs may still
be relevant targets for preventing neuronal death. Our data, how-
ever, present the field with an important tale of caution about
overinterpreting results obtained with HDACi and make the
argument that an interdisciplinary approach emphasizing the
close interaction between both chemical design of compounds
and biological testing is needed if we are going to interpret
accurately the wealth of the data available from pharmacolog-
ical interventions.
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